<?xml version="1.0" encoding="UTF-8"?>
<p>Therefore, societies including the American College of Cardiology (ACC) have supported the continuation of RAAS inhibitors in patients in otherwise stable condition who are at risk for, are being evaluated for, or have been diagnosed with COVID-19 (
 <xref rid="B40" ref-type="bibr">40</xref>). The ACC advises that patients should continue taking RAAS inhibitors for conditions such as heart failure, hypertension, or ischemic heart disease, and that if COVID-19 occurs, “individualized treatment decisions should be made according to each patient's hemodynamic status and clinical presentation” (
 <xref rid="B44" ref-type="bibr">44</xref>).
</p>
